Title |
CGDnet: Cancer Gene Drug Network: Using patient-specific drug-gene networks for recommending targeted cancer therapies.
|
Institution |
GEORGETOWN UNIVERSITY, WASHINGTON, DC
|
Principal Investigator |
BOCA, SIMINA
|
NCI Program Director |
Witherspoon
|
Cancer Activity |
Clinical Oncology
|
Division |
DCTD
|
Funded Amount |
$215,336
|
Project Dates |
06/06/2017 - 05/31/2019
|
Fiscal Year |
2017
|
Project Type |
Grant
|
Research Topics w/ Percent Relevance |
Cancer Types w/ Percent Relevance |
Cancer (100.0%)
|
N/A
|
Research Type |
Resources and Infrastructure Related to Treatment and the Prevention of Recurrence
|
Abstract |
"PROJECT SUMMARY/ABSTRACT: Molecular profiling - the practice of molecularly testing tumors in order to find specific gene or protein alterations which can be used to recommend targeted therapies - is increasingly used in oncology and is fast becoming a major part of precision medicine. In practice, each patient or physician generally receives a list of molecular anomalies and a list of therapies which are predicted to be beneficial or not beneficial based on the tumor molecular profile. This may lead to a difficult process of prioritizing therapies for individual patients. In the current proposal, we will develop computational network-based approaches to therapy recommendation by using existing resources to inform the connections between drugs and gene or protein variants. We will consider approaches both for creating "average" networks based on population-level data and for creating "patient-specific" networks based on an individual?s specific tumor profile. We will also design and implement an interactive data visualization approach for these networks which will be usable by both clinical researchers and clinicians. The methods and tools developed as part of this project will be entirely reproducible and shared with the community via open-source software packages and interactive tools. We believe our project could eventually lead the way to improving the way therapies are targeted to cancer patients." |